Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold small blocks of common stock to cover taxes on restricted stock unit (RSU) vesting. On January 27, 2026, he sold 886 shares at $240.5313 per share. On January 28, 2026, he sold an additional 1,000 shares at $237.6624 per share.
Both sales were made under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) and were specifically to satisfy tax withholding and remittance obligations tied to previously granted RSUs. After these transactions, Rabinowitz directly owned 225,147 shares of Natera common stock.
Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, reported small insider sales of common stock tied to RSU vesting. On January 27, 2026, he sold 1,013 shares at $240.5313, and on January 28, 2026 he sold 1,200 shares at $237.6624.
The filing states both sales were made to satisfy tax withholding and remittance obligations from restricted stock unit vesting, under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, he directly owns 142,486 shares of Natera common stock.
Natera, Inc. officer John Fesko reported small automatic sales of common stock tied to restricted stock unit vesting. On January 27, 2026, he sold 784 shares at $240.5313 each, and on January 28, 2026 he sold 928 shares at $237.6624 each. The transactions were made to satisfy tax withholding and remittance obligations under pre-set instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these sales, he beneficially owned 175,540 shares of Natera common stock directly.
Natera insider Michael Brophy has filed a Form 144 indicating an intent to sell 1,867 shares of Natera common stock. These shares were acquired on 01/27/2026 as restricted stock units from the issuer and are to be sold through Morgan Stanley Smith Barney LLC on or about 01/29/2026 on NASDAQ, with an aggregate market value of $440,481.31. Natera had 138,014,465 shares of common stock outstanding.
The filing also lists recent sales under a Rule 10b5-1 trading plan for Michael Brophy, including 1,176 shares sold on 01/28/2026 for $279,232.73 and 36,573 shares sold on 01/21/2026 for $8,875,115.05, as well as additional direct sales on 01/20–21/2026.
Michael Brophy has filed a Rule 144 notice covering the planned sale of 1,176 shares of common stock, with an aggregate market value of 282,639.84. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with 138,014,465 shares outstanding.
The 1,176 shares were acquired on 01/26/2026 as restricted stock units from the issuer, with the same date listed as payment. Over the past three months, Brophy and a 10b5-1 sales plan have already sold additional common shares, including 36,573 shares for 8,875,115.05 and 23,948 shares for 5,621,515.20.
Natera, Inc. director and co-founder Sheena Jonathan reported multiple sales of Natera common stock on January 23, 2026 by two trusts associated with her. Caraluna 1 Trust sold an aggregate 750 shares in several trades at weighted average prices between about $242.02 and $245.19 per share, leaving it with holdings between 21,782 and 22,372 shares after each trade. Caraluna 2 Trust sold a total of 750 shares in similar transactions at weighted average prices ranging from $242.13 to $245.39 per share, ending with 21,782 shares after the last transaction. These sales were carried out under a Rule 10b5-1 trading plan adopted on June 7, 2024. Jonathan also reports 264,078 shares held directly. The trust-held shares are for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those securities.
JPMorgan Chase & Co. reports beneficial ownership of 12,825,640 shares of Natera, Inc. common stock, representing 9.1% of the outstanding class as of 12/31/2025. JPMorgan has sole voting power over 11,614,632 shares and shared voting power over 3,670 shares, and it has sole dispositive power over 12,812,792 shares and shared dispositive power over 11,783 shares.
The filing identifies multiple JPMorgan subsidiaries involved in holding these shares, including J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and several asset management entities. JPMorgan certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Natera.
Natera, Inc. CEO and President Steven Leonard Chapman reported routine equity transactions involving company stock. On January 20, 2026, he exercised 3,386 Restricted Stock Units, each representing one share of Natera common stock, and received the same number of shares. That day he sold 71,932 shares of common stock at an average price of $234.7384 per share to cover tax withholding and remittance obligations related to RSU vesting, under a pre-set instruction intended to satisfy Rule 10b5‑1(c). On January 21, 2026, he sold an additional 1,590 shares of common stock at $235 per share, also to satisfy tax obligations tied to RSU vesting.
After these transactions, Chapman beneficially owned 219,150 shares of Natera common stock directly. The RSUs referenced vest over four years, with 25% having vested on January 20, 2023 and the remainder vesting in 12 equal quarterly installments thereafter.
Natera, Inc. CFO Michael Burkes Brophy reported multiple stock transactions tied to RSU vesting and a preset trading plan. On January 20, 2026, he sold 23,948 shares of common stock at an average price of $234.7384 per share and had 1,522 Restricted Stock Units convert into the same number of common shares at an exercise price of $0. On January 21, 2026, he sold 602 shares at $235 per share and 36,573 shares at an average price of $242.6685 per share. The filing states that certain sales were made to cover tax withholding obligations upon RSU vesting and that the reported sales were executed under a Rule 10b5-1 trading plan. Following these transactions, he directly owned 64,123 shares of Natera common stock.
Natera, Inc. co-founder and director Sheena Jonathan reported January 2026 stock transactions involving common shares and restricted stock units (RSUs). On January 20, 2026, she sold 2,981 common shares at a weighted average price of $234.7384, in a sale described as satisfying tax withholding obligations tied to RSU vesting, and 191 RSUs converted into the same number of common shares. On January 21, 2026, she reported additional sales of 93, 2,470, and 600 common shares at weighted average prices of $235, $234.1157, and $235.8183, including trades made under a Rule 10b5-1 trading plan adopted on June 7, 2024. Following these transactions, she directly held 264,078 common shares and indirectly held 22,532 common shares in each of two trusts named Caraluna 1 Trust and Caraluna 2 Trust.